Navigation Links
RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
Date:5/16/2013

LA JOLLA, Calif. and SHANGHAI, May 16, 2013 /PRNewswire/ -- RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new paradigm in the treatment of autoimmune diseases and cancer.

"RYI-008, with its unprecedented femtamolar potency and amazing long half-life has a therapeutic profile of once monthly, low milligram, subcutaneous dosing," said Paul Grayson , president and CEO of RuiYi. "RYI-008 is a tremendous candidate for this novel development strategy, with approximately 4.1 million biologic treatment naive rheumatoid arthritis patients in China in need of a cost effective therapeutic option.  The team at Genor has deep global development experience and strong commercial, regulatory, and government relationships in China, making them the ideal development partner. We look forward to working with them to deliver novel, breakthrough therapeutics for the Chinese healthcare system."

Joe Zhou , CEO of Genor BioPharma, commented, "The clinical data on IL-6 modulation continues to be extremely favorable in multiple diseases.  The selection by RuiYi and Genor of RYI-008 for development shows a unique understanding of a changing healthcare environment in China where the cost-effective delivery of novel efficacious medicines is of significant importance."

About RYI-008

RYI-008, also known as ARGX-109, is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. The antibody was discovered by arGEN-X, Ghent Belgium, utilizing the arGEN-X SIMPLE AntibodyTM technology, and exclusively license to RuiYi to develop and commercialize globally. 

About RuiYi

RuiYi is focused on the discovery and development of novel biologic therapeutics that meet medical and commercial needs for China's patients and healthcare system and that have the potential to be disruptive globally. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company's technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi's executive management team has offices in La Jolla, California, and RuiYi's discovery efforts and research facility are located in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, China.  For more, visit www.ruiyibio.com.

About Genor BioPharma

Founded in 2007, Genor Biopharma Co. Ltd. is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusion proteins. With a total investment of approximately $30 million, Genor has more than 10 products in the pipeline, three of which are at IND and clinical stages.  Genor has a team of approximately 110 employees, with key management members who have integrated expertise and experience in mAb drug research and development from leading Western biotech and pharmaceutical companies. Genor has established a 6,000 m2 R&D center, which includes R&D and process development labs, analytical and quality center, and a cGMP clinical production facility and is planning a commercial-scale cGMP production facility. For more, visit http://www.genorbio.com.


'/>"/>
SOURCE RuiYi Inc.; Genor BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CMC Biologics und RuiYi Enter treffen Vereinbarung zur Entwicklung eines neuartigen monoklonalen Anti-IL-6-Antikörpers
2. CMC Biologics et RuiYi passent un accord pour le développement dun nouvel anticorps monoclonal Anti-IL-6
3. CMC Biologics and RuiYi Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody
4. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
5. Callidus Biopharma Announces $4.6 million in Series A Financing to Pursue Orphan Disease Therapies
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
7. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
8. PDL BioPharma to Announce First Quarter 2013 Financial Results on May 9, 2013
9. Rutgers Business School and the Blanche and Irwin Lerner Center will explore trends and issues facing the biopharmaceutical industry at a healthcare symposium, Tuesday, April 30
10. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
11. New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... PARIS , le 27 Avril 2016 /PRNewswire/ ... chiffre d,affaires a progressé de +5% sur le ... ventes récurrentes de consommables  Croissance de ... Mauna Kea Technologies (Euronext : ... multidisciplinaire d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre ...
(Date:4/27/2016)... NEW DELHI , April 27, 2016 ... CSR initiative to save newborns ... ,s hospital for women & newborns in collaboration with Breast ... has launched the first Pasteurized Human Milk Bank, ,Amaara, in ... the best nutritional food source for infants and should be ...
(Date:4/27/2016)... 2016 Global  urinalysis market ... by 2022, according to a new report by ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation ... and accuracy delivered by the new generation urinalysis ... urinalysis instruments and consumables. For instance, the automatic ...
Breaking Medicine Technology:
(Date:4/30/2016)... Macomb, Michigan (PRWEB) , ... ... ... report published by CBC News on April 4th, 2016 questioned the use ... organization referred to EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally ...
(Date:4/29/2016)... ... 2016 , ... World Patent Marketing , a vertically ... automotive invention that improves the storage features of a pick up truck. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Over the next five ...
(Date:4/29/2016)... MA (PRWEB) , ... April 29, 2016 , ... ... the Two Ten Footwear Foundation, the national charitable foundation serving the footwear industry, ... With 8,000 volunteers representing more than 130 companies across 23 states during the ...
(Date:4/29/2016)... ... 29, 2016 , ... Our bodies are bombarded daily by environmental and lifestyle ... these stressors is to adopt a more healthful diet, but too many people think ... certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
Breaking Medicine News(10 mins):